162 related articles for article (PubMed ID: 37903321)
1. Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis.
Verkamp B; Zoref-Lorenz A; Francisco B; Kieser P; Mack J; Blackledge T; Brik Simon D; Yacobovich J; Jordan MB
Blood Adv; 2023 Dec; 7(23):7258-7269. PubMed ID: 37903321
[TBL] [Abstract][Full Text] [Related]
2. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
[TBL] [Abstract][Full Text] [Related]
3. Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review.
Croden J; Bilston L; Taparia M; Grossman J; Sun HL
Ann Hematol; 2022 Oct; 101(10):2297-2306. PubMed ID: 35978181
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society.
Ehl S; Astigarraga I; von Bahr Greenwood T; Hines M; Horne A; Ishii E; Janka G; Jordan MB; La Rosée P; Lehmberg K; Machowicz R; Nichols KE; Sieni E; Wang Z; Henter JI
J Allergy Clin Immunol Pract; 2018; 6(5):1508-1517. PubMed ID: 30201097
[TBL] [Abstract][Full Text] [Related]
5. Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation.
Böhm S; Wustrau K; Pachlopnik Schmid J; Prader S; Ahlmann M; Yacobovich J; Beier R; Speckmann C; Behnisch W; Ifversen M; Jordan M; Marsh R; Naumann-Bartsch N; Mauz-Körholz C; Hönig M; Schulz A; Malinowska I; Hines M; Nichols KE; Gil-Herrera J; Talano JA; Crooks B; Formankova R; Jorch N; Bakhtiar S; Kühnle I; Streiter M; Nathrath M; Russo A; Dürken M; Lang P; Lindemans C; Henter JI; Lehmberg K; Ehl S
Blood; 2024 Mar; 143(10):872-881. PubMed ID: 37992218
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children.
Pan H; Wang G; Guan E; Song L; Song A; Liu X; Yi Z; Sun LR
BMC Pediatr; 2020 Jun; 20(1):288. PubMed ID: 32517812
[TBL] [Abstract][Full Text] [Related]
7. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution.
Gupta AA; Tyrrell P; Valani R; Benseler S; Abdelhaleem M; Weitzman S
J Pediatr Hematol Oncol; 2009 Feb; 31(2):81-4. PubMed ID: 19194188
[TBL] [Abstract][Full Text] [Related]
8. Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT.
Kobayashi R; Tanaka J; Hashino S; Ota S; Torimoto Y; Kakinoki Y; Yamamoto S; Kurosawa M; Hatakeyama N; Haseyama Y; Sakai H; Sato K; Fukuhara T
Bone Marrow Transplant; 2014 Feb; 49(2):254-7. PubMed ID: 24037021
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.
Marsh RA; Jordan MB; Talano JA; Nichols KE; Kumar A; Naqvi A; Vaiselbuh SR;
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786410
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
Ma H; Zhang R; Zhang L; Wei A; Zhao X; Yang Y; Liu W; Li Z; Qin M; Wang T
Ann Hematol; 2020 Oct; 99(10):2255-2263. PubMed ID: 32766934
[TBL] [Abstract][Full Text] [Related]
11. Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy.
Rajajee S; Ashok I; Manwani N; Rajkumar J; Gowrishankar K; Subbiah E
Indian J Pediatr; 2014 Dec; 81(12):1337-41. PubMed ID: 24806152
[TBL] [Abstract][Full Text] [Related]
12. Outcome analysis of pediatric hemophagocytic lymphohistiocytosis.
Chen TY; Hsu MH; Kuo HC; Sheen JM; Cheng MC; Lin YJ
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):172-179. PubMed ID: 32307323
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.
Henter JI; Samuelsson-Horne A; Aricò M; Egeler RM; Elinder G; Filipovich AH; Gadner H; Imashuku S; Komp D; Ladisch S; Webb D; Janka G;
Blood; 2002 Oct; 100(7):2367-73. PubMed ID: 12239144
[TBL] [Abstract][Full Text] [Related]
14. Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2.
Segal JE; Daley JD; Barnum JL; Salgado CM; Reyes-Mugica M; Schneider C; Gumus S; Thakrar D; Allen SW; Canna SW
J Clin Immunol; 2021 Jul; 41(5):987-991. PubMed ID: 33570715
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
[TBL] [Abstract][Full Text] [Related]
16. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.
Bergsten E; Horne A; Aricó M; Astigarraga I; Egeler RM; Filipovich AH; Ishii E; Janka G; Ladisch S; Lehmberg K; McClain KL; Minkov M; Montgomery S; Nanduri V; Rosso D; Henter JI
Blood; 2017 Dec; 130(25):2728-2738. PubMed ID: 28935695
[TBL] [Abstract][Full Text] [Related]
17. Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis.
Lee BJ; Cao Y; Vittayawacharin P; É'Leima G; Rezk S; Reid J; Brem EA; Ciurea SO; Kongtim P
Eur J Haematol; 2023 Sep; 111(3):477-484. PubMed ID: 37385631
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of mycobacterial infection associated hemophagocytic lymphohistiocytosis with etoposide and anti-tuberculous therapy: a case report.
Wang YH; Ba JH; Shi XW; Wu BQ
BMC Infect Dis; 2020 May; 20(1):321. PubMed ID: 32370734
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.
Marsh RA; Allen CE; McClain KL; Weinstein JL; Kanter J; Skiles J; Lee ND; Khan SP; Lawrence J; Mo JQ; Bleesing JJ; Filipovich AH; Jordan MB
Pediatr Blood Cancer; 2013 Jan; 60(1):101-9. PubMed ID: 22522603
[TBL] [Abstract][Full Text] [Related]
20. sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study.
Wimmer T; Mattes R; Stemmler HJ; Hauck F; Schulze-Koops H; Stecher SS; Starck M; Wendtner CM; Bojko P; Hentrich M; Nickel KE; Götze KS; Bassermann F; von Bergwelt-Baildon M; Spiekermann K
Blood Adv; 2023 Mar; 7(5):832-844. PubMed ID: 35973195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
